Phase 3 Recruiting NIH
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06422806
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- UM Sylvester Comprehensive Cancer Center at Hollywood — Hollywood, Florida
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Florida: - Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
- Nicklaus Children's Hospital — Miami, Florida
- Arnold Palmer Hospital for Children — Orlando, Florida
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in Florida: - Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 3 Recruiting Network
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…
Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in Florida: - Broward Health Medical Center — Fort Lauderdale, Florida
- Golisano Children's Hospital of Southwest Florida — Fort Myers, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
- Nemours Children's Clinic-Jacksonville — Jacksonville, Florida
Phase 3 Recruiting Network
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Sites in Florida: - Univ of Florida Health Science Ctr - Gainesville — Gainesville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida
- Moffitt Cancer Center-International Plaza — Tampa, Florida
- Moffitt Cancer Center - McKinley Campus — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…
Sponsor: NRG Oncology
NCT ID: NCT05646316
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- UM Sylvester Comprehensive Cancer Center at Kendall — Miami, Florida
Phase 3 Recruiting Industry
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Sponsor: Polaris Group
NCT ID: NCT05712694
Sites in Florida: - Mayo Clinic Florida — Jacksonville, Florida
- University of Miami/ Sylvester Comprehensive Cancer Center — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Indepe…
Sponsor: PharmaMar
NCT ID: NCT06088290
Sites in Florida: - Mayo Clinic - Jacksonville — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride…
Sponsor: Advenchen Laboratories, LLC
NCT ID: NCT03016819
Sites in Florida: - Mayo Clinic Jacksonville — Jacksonville, Florida
- University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
Phase 3 Recruiting Industry
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral on…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06345729
Sites in Florida: - Mount Sinai Cancer Center ( Site 0137) — Miami Beach, Florida
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Florida: - Memorial Healthcare System — Hollywood, Florida
- Local Institution - 2113 — Tampa, Florida
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Florida: - H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
Sponsor: Pierre Fabre Medicament
NCT ID: NCT04554914
Sites in Florida: - Sylvester Comprehensive Cancer Center/ University of Miami — Miami, Florida
- Moffit Cancer Center (Adults only) — Tampa, Florida
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people wi…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05634369
Sites in Florida: - University of Florida — Gainesville, Florida
- Nemours Jacksonville — Jacksonville, Florida
- University of Miami — Miami, Florida
- Johns Hopkins All Children's Hospital — St. Petersburg, Florida
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \…
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06541262
Sites in Florida: - University of Florida — Gainesville, Florida
- Nicklaus Children's Hospital — Miami, Florida
- Arnold Palmer Hospital for Children — Orlando, Florida
- All Children's Hospital Johns Hopkins Medicine — St. Petersburg, Florida
- St. Joseph's Children's Hospital — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Florida: - Local Institution - 2105 — Orlando, Florida
- Local Institution - 2120 — Orlando, Florida
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Florida: - Johns Hopkins All Children's Hospital ( Site 1025) — St. Petersburg, Florida
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Florida: - Florida Cancer Specialists & Research Institute — Lake Mary, Florida
- Sylvester Comprehensive Cancer Center — Miami, Florida
Phase 1, Phase 2 Recruiting Industry
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants wi…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05734066
Sites in Florida: - Johns Hopkins All Children's Hospital — St. Petersburg, Florida
Phase 2 Recruiting Network
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sponsor: AIDS Malignancy Consortium
NCT ID: NCT04305691
Sites in Florida: - University of Miami Miller School of Medicine — Miami, Florida
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Florida: - Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus — Fort Myers, Florida
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any …
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06465199
Sites in Florida: - Nicklaus Children's Hospital — Miami, Florida
- Arnold Palmer Hospital for Children — Orlando, Florida
- St. Joseph's Children's Hospital — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd…
Sponsor: GI Innovation, Inc.
NCT ID: NCT05824975
Sites in Florida: - Mayo Clinic in Florida — Jacksonville, Florida
Phase 1, Phase 2 Recruiting Industry
This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous…
Sponsor: Haihe Biopharma Co., Ltd.
NCT ID: NCT04390737
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
Sponsor: Adcendo ApS
NCT ID: NCT06797999
Sites in Florida: - University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida